Immune dysfunction in COVID-19 and judicious use of anti-rheumatic drugs for the treatment of hyperinflammation

Turk J Med Sci. 2021 Nov 30. doi: 10.3906/sag-2110-179. Online ahead of print.ABSTRACTIn the Wuhan province of China, almost two years ago, in December 2019, the novel Coronavirus 2019 has caused a severe involvement of the lower respiratory tract leading to an acute life-threatening respiratory syndrome, coronavirus disease-19 (COVID-19). Subsequently, coronavirus 2 (SARS-CoV-2) rapidly spread to entire world causing a pandemic and affected every single person on earth either directly or indirectly with destroying all faucets of social life and economy. Since the announcement of COVID-19 as a global pandemic, we witnessed a tremendous scientific work on all aspects of COVID-19 across the globe which has never been witnessed before. The most remarkable achievement would be the introduction of vaccines which provide protection from the severe infection and is the only premise for the control of disease. However, despite the tremendous work, the number of treatments either antiviral or immunomodulatory for infected patients are considerably limited, yet disease is causing substantial morbidity and mortality. COVID-19 follows heterogenous disease course among infected individuals and dysregulated immune system is primarily responsible for the worse outcomes. Immun deficiency, being on corticosteroids for inflammatory diseases, delayed interferon response and advanced age adversely influence prognosis with impairing viral clearance. On the other hand, exuberant immune response wi...
Source: Turkish Journal of Medical Sciences - Category: General Medicine Authors: Source Type: research